Greenwich LifeSciences (GLSI) Operating Income (2019 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Operating Income came in at -$7.9 million in Q4 2025, up 18.17% YoY from -$6.7 million in Q4 2024, and down 90.32% on a QoQ basis from -$4.2 million in Q3 2025.
Greenwich LifeSciences (GLSI) Operating Income (2019 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 7 years of Operating Income data on file, last reported at -$7.9 million in Q4 2025.
- Quarterly Operating Income rose 18.17% year-over-year to -$7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.4 million (down 10.27% YoY) and the FY2025 annual result came in at -$19.4 million, down 10.27% from the prior year.
- Operating Income slipped to -$7.9 million in Q4 2025, from -$4.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$600606.0 in Q1 2021 to a low of -$9.7 million in Q4 2024.
- A 5-year average of -$3.0 million and a median of -$2.5 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income plunged 258.05% — and 2025, when it advanced 18.17%.
- Tracing GLSI's Operating Income over 5 years: stood at -$2.4 million in 2021, then decreased by 21.77% to -$2.9 million in 2022, then increased by 2.03% to -$2.8 million in 2023, then slumped by 242.36% to -$9.7 million in 2024, then increased by 18.17% to -$7.9 million in 2025.
- The last three Operating Income figures came in at -$7.9 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Greenwich LifeSciences | 246.39 Mn | 246.39 Mn | - | -5.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.73 Mn |
| Dec 31, 2025 | -7.94 Mn |
| Sep 30, 2025 | -4.17 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Mar 31, 2025 | -3.28 Mn |
| Dec 31, 2024 | -9.71 Mn |
| Sep 30, 2024 | -2.73 Mn |
| Jun 30, 2024 | -2.66 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | -2.84 Mn |
| Sep 30, 2023 | -2.50 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -2.24 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -2.38 Mn |
| Jun 30, 2022 | -773,307.00 |
| Mar 31, 2022 | -1.99 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -866,686.00 |
| Jun 30, 2021 | -753,445.00 |